Research

Moderna Stock: Melanoma Trial Evidence and Cash Use

Moderna stock analysis starts with Merck's August 19, 2026 melanoma trial update: recurrence and distant-metastasis endpoints were met, while overall survival remains under follow-up. Approval, safety, delivery and cash use still limit conclusions about commercial value and future share prices.

2026-10-09 · 10 min read

Research

Nvidia Stock Analysis: $230 Resistance vs. $235 Billion Buyback Signal

Nvidia stock analysis separates $235 billion in buyback capacity through fiscal 2028 from evidence of sustained AI-driven earnings growth. Price support depends on actual repurchases; authorization alone does not establish a price floor.

2026-10-09 · 12 min read

Research

Adobe Generative AI Stock Analysis: The Freemium Conversion Thesis

Adobe trades near 11.2x NTM P/E and 8.4x NTM EV/EBITDA, a discount that already embeds much of the bad outcome from generative AI disruption, but the central risk is that free users never convert at Reader-era rates, diluting a healthy subscription business through 2026 and 2027.

2026-10-09 · 11 min read

Research

Teradyne TER Stock Analysis: AI Revenue Growth vs. Rich Valuation Risk

Teradyne TER stock analysis reveals a company where AI-driven revenue more than doubled, yet a rich P/E near 46.9 and a DCF suggesting 39% overvaluation create a clear boundary for the bull case. The thesis holds as long as AI capex sentiment and margin trends support the premium.

2026-10-09 · 11 min read

Research

Nebius NBIS Stock Analysis: Weighing the Data on Valuation Structure

Nebius NBIS stock analysis presents the thesis, evidence thread, market structure, and boundary conditions. BiFu readers get concrete signals to compare, source limits to respect, and risk-aware context in the finished draft without unsupported figures, price calls, or overextended conclusions.

2026-10-09 · 9 min read

Research

Azure AI Growth: Evidence, Mechanism, and Key Risks

Microsoft Azure AI growth analysis reveals a cloud-AI flywheel that is producing rare pricing power in enterprise computing. Azure revenues grew 43% year over year in the fiscal fourth quarter ended June 30, 2026, with management noting that customer demand continues to exceed available capacity.

2026-10-09 · 6 min read

Research

GE Vernova's 116 GW Backlog and the Limits of the Stock Forecast

GE Vernova's stock forecast hinges on a record $176B backlog and gas turbines sold out through 2030, yet 60x forward earnings and wind losses test the bull case. The evidence shows strong demand, but the price already reflects much of it.

2026-10-09 · 8 min read

Research

Symbotic SYM Stock Analysis: Evidence From The Evidence Thread

Symbotic SYM stock analysis reveals a structural constraint: the 17.8% GF Value upside to $53.46 is contradicted by a 25% EPS miss against consensus and 53 insider sales in six months. The stock's trajectory depends on whether analyst estimate revisions stabilize or continue downward.

2026-10-09 · 8 min read

Research

Cognizant CTSH Stock Analysis: Weighing the Data on Boundary Condition

Cognizant's balance sheet, with an Altman-Z score of 5.30 and debt-to-free-cash-flow ratio of 0.60, supports a stable dividend thesis, but the stock's re-rating depends on AI pipeline conversion into billable revenue that has not yet appeared in reported numbers.

2026-10-09 · 7 min read

Research

Rally Mechanics: Workday's Margin Gains Meet Buyout Financing Risk

Workday's July 2026 rally is best read as a margin-revision story rather than a pure growth re-rating, and the evidence boundary that matters is whether AI monetization can offset longer sales cycles before the valuation multiple compresses.

2026-10-09 · 8 min read